Updated: Feb 11, 2022
GOLD looks back at the pharmaceutical industry’s top news stories from the past few months, covering topics such as the latest COVID-19 developments, the most prominent drug approvals and the most prestigious mergers and acquisitions
New report by IndexBox reveals that 2021 global vaccine trade surpasses $42bn.
Roche and Foundation Medicine launch a genomic profiling kit.
Takeda acquires London-based biotechnology company GammaDelta Therapeutics.
Novartis’ Scemblix (asciminib) gains FDA approval for the treatment of chronic myeloid leukaemia.
Novavax receives its first emergency use authorisation for its COVID-19 vaccine in Indonesia.
MHRA authorises Merck and Ridgeback’s oral COVID-19 antiviral Lagevrio (molnupiravir).
Pfizer’s COVID-19 antiviral treatment shows 89% reduction in hospitalisation and death risk.
Sanofi invests up to $60m in retinal gene therapy company Gyroscope Therapeutics.
Novartis launches unique initiative to supply low- and lower-middle-income countries with affordable access to COVID-19 treatments.
Pfizer signs deal with Medicines Patent Pool to increase access to its COVID-19 treatment for lower-income countries.
FDA approves Merck’s Keytruda (pembrolizumab) for adjuvant treatment for certain patients with renal cell carcinoma.
Novo Nordisk announces acquisition of Massachusetts-based Dicerna Pharmaceuticals for $3.3bn.